Balaxi Pharmaceuticals (BALAXI) Q1 26/27 earnings summary

Executive summary

• Achieved 14% year-over-year revenue growth in Q1 FY27, with improved profitability and gross margin expansion of 241 basis points to 46.5%.

• Profit after tax rose to ₹1.29 crore from ₹0.29 crore in Q1 FY26, reflecting a 347% increase.

• Approved unaudited standalone and consolidated financial results for the quarter ended 30th June 2026.

• Commercial production commenced at the new pharmaceutical formulation facility in Hyderabad/Jadcherla, with 31 products approved and scaling up.

• WHO-GMP audit conducted at the new facility; CAPA response submitted and certification process underway.

Financial highlights

• Q1 FY27 consolidated revenue: ₹80.68 crore (up 14.1% YoY); gross profit: ₹37.51 crore (up 20.3% YoY).

• Consolidated net profit for Q1 FY27 stood at ₹129.74 lakhs, compared to ₹29.01 lakhs in Q1 FY26.

• Gross margin improved to 46.5% from 44.1% YoY; EBITDA at ₹4.66 crore (up 12.4% YoY); EBITDA margin at 5.8%.

• PAT margin increased to 1.6% from 0.4% YoY; EPS rose to ₹0.24 from ₹0.05 YoY.

• FY26 revenue declined 7.7% YoY to ₹270.17 crore; gross margin improved to 44.2%.

Outlook and guidance

• Focus remains on expanding institutional business and presence in Africa and Latin America.

• Ongoing expansion of product portfolio and manufacturing operations at the new facility, with further product approvals being pursued.

• WHO-GMP certification expected to enhance manufacturing credentials and support future growth.

• Strategic exit from Ancillary Building Hardware business to improve working capital efficiency.